BioAtla, Inc. (NASDAQ:BCAB) Short Interest Update

BioAtla, Inc. (NASDAQ:BCAB) saw a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 4,380,000 shares, a decline of 13.4% from the January 15th total of 5,060,000 shares. Based on an average trading volume of 1,110,000 shares, the short-interest ratio is currently 3.9 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vontobel Holding Ltd. bought a new stake in shares of BioAtla in the third quarter valued at approximately $28,000. Chicago Partners Investment Group LLC acquired a new position in BioAtla in the 3rd quarter valued at $44,000. GSA Capital Partners LLP bought a new stake in shares of BioAtla during the 3rd quarter valued at $623,000. Massachusetts Financial Services Co. MA grew its holdings in shares of BioAtla by 5.2% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 569,332 shares of the company’s stock worth $1,002,000 after purchasing an additional 28,133 shares in the last quarter. Finally, XTX Topco Ltd increased its position in shares of BioAtla by 7.2% in the third quarter. XTX Topco Ltd now owns 154,967 shares of the company’s stock worth $273,000 after purchasing an additional 10,384 shares during the period. Institutional investors and hedge funds own 77.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright lowered BioAtla from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 13th.

BioAtla Stock Performance

NASDAQ:BCAB traded up $0.03 during mid-day trading on Monday, reaching $0.46. 1,711,107 shares of the company’s stock were exchanged, compared to its average volume of 665,159. BioAtla has a one year low of $0.38 and a one year high of $4.02. The business’s fifty day simple moving average is $0.68 and its two-hundred day simple moving average is $1.41. The firm has a market capitalization of $22.46 million, a PE ratio of -0.27 and a beta of 1.14.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.